Verastem
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
117 Kendrick St Ste 500, Needham, Massac...Phone Number
(514) 954-4000Website
www.verastem.comRevenue
$49.6 MillionStock Symbol
VSTMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Verastem
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on drug discovery and development to improve outcomes for cancer patients. Verastem is currently developing Duvelisib, a dual inhibitor of PI3K-Delta and PI3K-Gamma, which successfully met its primary endpoint in a Phase 2 study in iNHL and is currently being evaluated in a Phase 3 clinical trial in patients with CLL. Verastem is also developing the FAK inhibitor defactinib, which is currently being investigated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various types of cancer, including pancreatic cancer, ovarian cancer, non-small cell lung cancer and mesothelioma. Verastem's product candidates seek to treat cancer by modulating the local tumor microenvironment, improving anti-tumor immunity, and reducing cancer stem cells.Explore more
Verastem Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Verastem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Verastem
Check out if Verastem is spiking on competitors!
Click to see if Verastem had a recent Job posting/layoffs
Earning: See what the market has to say on Verastem recently announced quarterly report
Verastem, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Verastem launches new products
Check if Verastem has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Verastem has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Verastem
Compare insights from companies similar to Verastem, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Verastem is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Verastem is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Verastem.
Verastem financials insights
Gather financial insights about Verastem, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Stock Offering
$63.3M
Unspecified
$2M
2014
Other Financing Round
$3.9M
2015
Stock Offering
$50.9M
2017
Stock Offering
$25M
2018
Multiple Rounds
$131.1M
2020
Debt
$4.8M
Share Placement
$100M
2022
Debt
$150M
Verastem Tech Stack
A closer look at the technologies used by Verastem
See more technologies
Most Recent Scoops
Project
Verastem has announced that, following FDA feedback, it will advance separate Phase II registration-directed protocols for each of its three tumor type indications CRC, lung, and PDAC incorporating blinded independent central review and other elements required for registration-directed studies.
Medical Research, Clinical Operations
Project
Verastem has deployed medical affairs, MSL, and oncology nurse educator teams to address premature discontinuation of AVMAPKI FAKZYNJA CO-PACK, focusing on educating physicians and staff that side effects attenuate over time unlike chemotherapy and that patients should return to their starting dose after any brief pause per label guidance.
Training, Learning & Development, Doctors / Physicians, Medical Education & Training, Pharmaceuticals
Project
Verastem has reported that the commercial launch of AVMAPKI FAKZYNJA progressed through its first three quarters with continued growth, including a Q1 increase over Q4, following which the company conducted a comprehensive six-month launch review and appointed a new Chief Commercial Officer to lead go-forward commercial strategy.
Executive Moves, Corporate Strategy
Project
Verastem has outlined its clinical combination strategy for its lead oncology asset, including combinations with gemcitabine and cetuximab in PDAC, PD-1 inhibitors in lung, and cetuximab in CRC, while also evaluating single-agent potential based on response rates of 58% in second-line PDAC and 69% in lung observed in Chinese trial data.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals, Clinical Operations
Verastem News & Media
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors - Yahoo Finance
BOSTON, May 26, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026.Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment
Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a dose-escalation trial of vs-7375, an oral KRAS G12D (on/off) inhibitor, in patients with KRAS G12D-mutant solid tumors. The preliminary safety and tolerability data indicate that VS-7375 can […]Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects
Verastem, Inc. (NASDAQ:VSTM) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company progresses with its Phase 3 ovarian cancer trial while AVMAPKI FAKZYNJA CO-PACK generates revenue. Verastem, Inc. (NASDAQ:VSTM), operating from its headquarters in Massachusetts, is a development-stage biopharmaceutical company. Its focus is on discovering and commercializing novel cancer therapies, […]Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Verastem
Sign Up For FreeTo access detailed company insights
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on drug discovery and development to improve outcomes for cancer patients. Verastem is currently developing Duvelisib, a dual inhibitor of PI3K-Delta and PI3K-Gamma, which successfully met its primary endpoint in a Phase 2 study in iNHL and is currently being evaluated in a Phase... Read More
